• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青光眼的神经保护:NAD/NADH 氧化还原状态作为潜在的生物标志物和治疗靶点。

Neuroprotection in Glaucoma: NAD/NADH Redox State as a Potential Biomarker and Therapeutic Target.

机构信息

NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London EC1V 9EL, UK.

Department of Clinical & Movement Neurosciences, UCL Queens Square Institute of Neurology, London NW3 2PF, UK.

出版信息

Cells. 2021 Jun 5;10(6):1402. doi: 10.3390/cells10061402.

DOI:10.3390/cells10061402
PMID:34198948
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8226607/
Abstract

Glaucoma is the leading cause of irreversible blindness worldwide. Its prevalence and incidence increase exponentially with age and the level of intraocular pressure (IOP). IOP reduction is currently the only therapeutic modality shown to slow glaucoma progression. However, patients still lose vision despite best treatment, suggesting that other factors confer susceptibility. Several studies indicate that mitochondrial function may underlie both susceptibility and resistance to developing glaucoma. Mitochondria meet high energy demand, in the form of ATP, that is required for the maintenance of optimum retinal ganglion cell (RGC) function. Reduced nicotinamide adenine dinucleotide (NAD) levels have been closely correlated to mitochondrial dysfunction and have been implicated in several neurodegenerative diseases including glaucoma. NAD is at the centre of various metabolic reactions culminating in ATP production-essential for RGC function. In this review we present various pathways that influence the NAD(H) redox state, affecting mitochondrial function and making RGCs susceptible to degeneration. Such disruptions of the NAD(H) redox state are generalised and not solely induced in RGCs because of high IOP. This places the NAD(H) redox state as a potential systemic biomarker for glaucoma susceptibility and progression; a hypothesis which may be tested in clinical trials and then translated to clinical practice.

摘要

青光眼是全球导致不可逆性失明的主要原因。其患病率和发病率随年龄和眼内压(IOP)水平呈指数级增长。目前,降低 IOP 是唯一被证明可以减缓青光眼进展的治疗方法。然而,尽管进行了最佳治疗,患者仍会丧失视力,这表明其他因素也会导致易感性。几项研究表明,线粒体功能可能是导致易感性和对青光眼发展的抵抗力的基础。线粒体以 ATP 的形式满足高能量需求,这是维持最佳视网膜神经节细胞(RGC)功能所必需的。还原型烟酰胺腺嘌呤二核苷酸(NAD)水平与线粒体功能障碍密切相关,并与包括青光眼在内的几种神经退行性疾病有关。NAD 是各种代谢反应的中心,最终导致 ATP 的产生——这对 RGC 功能至关重要。在这篇综述中,我们介绍了影响 NAD(H)氧化还原状态的各种途径,这些途径会影响线粒体功能,使 RGC 容易发生退化。由于 IOP 升高,这种 NAD(H)氧化还原状态的破坏是普遍存在的,而不仅仅是在 RGC 中诱导的。这将 NAD(H)氧化还原状态作为青光眼易感性和进展的潜在系统生物标志物;这一假设可以在临床试验中进行检验,然后转化为临床实践。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bd/8226607/a54347f23dc1/cells-10-01402-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bd/8226607/2da5ca39d8fa/cells-10-01402-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bd/8226607/0e2492b292ec/cells-10-01402-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bd/8226607/a54347f23dc1/cells-10-01402-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bd/8226607/2da5ca39d8fa/cells-10-01402-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bd/8226607/0e2492b292ec/cells-10-01402-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7bd/8226607/a54347f23dc1/cells-10-01402-g003.jpg

相似文献

1
Neuroprotection in Glaucoma: NAD/NADH Redox State as a Potential Biomarker and Therapeutic Target.青光眼的神经保护:NAD/NADH 氧化还原状态作为潜在的生物标志物和治疗靶点。
Cells. 2021 Jun 5;10(6):1402. doi: 10.3390/cells10061402.
2
Upregulation of the endothelin A (ET) receptor and its association with neurodegeneration in a rodent model of glaucoma.内皮素A(ET)受体上调及其与青光眼啮齿动物模型中神经退行性变的关联。
BMC Neurosci. 2017 Mar 1;18(1):27. doi: 10.1186/s12868-017-0346-3.
3
Regulated Cell Death of Retinal Ganglion Cells in Glaucoma: Molecular Insights and Therapeutic Potentials.青光眼致视网膜神经节细胞程序性死亡的研究进展
Cell Mol Neurobiol. 2023 Oct;43(7):3161-3178. doi: 10.1007/s10571-023-01373-1. Epub 2023 Jun 20.
4
Risk Factors for Retinal Ganglion Cell Distress in Glaucoma and Neuroprotective Potential Intervention.青光眼视网膜神经节细胞损伤的风险因素和神经保护的潜在干预作用。
Int J Mol Sci. 2021 Jul 27;22(15):7994. doi: 10.3390/ijms22157994.
5
Extracellular vesicle encapsulated nicotinamide delivered via a trans-scleral route provides retinal ganglion cell neuroprotection.经巩膜途径递送的细胞外囊泡包裹烟酰胺可提供视网膜神经节细胞保护。
Acta Neuropathol Commun. 2024 Apr 22;12(1):65. doi: 10.1186/s40478-024-01777-0.
6
Overexpression of parkin protects retinal ganglion cells in experimental glaucoma.Parkin 的过表达可保护实验性青光眼的视网膜神经节细胞。
Cell Death Dis. 2018 Jan 24;9(2):88. doi: 10.1038/s41419-017-0146-9.
7
The dark phase intraocular pressure elevation and retinal ganglion cell degeneration in a rat model of experimental glaucoma.实验性青光眼大鼠模型中的暗相眼压升高和视网膜神经节细胞变性。
Exp Eye Res. 2013 Jul;112:21-8. doi: 10.1016/j.exer.2013.04.008. Epub 2013 Apr 18.
8
The use of Nicotinamide and Nicotinamide riboside as an adjunct therapy in the treatment of glaucoma.将烟酰胺和烟酰胺核苷作为辅助疗法用于治疗青光眼。
Eur J Ophthalmol. 2023 Sep;33(5):1801-1815. doi: 10.1177/11206721231161101. Epub 2023 Mar 14.
9
NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function.NMNAT2 在青光眼 RGCs 中下调,并且 RGC 特异性基因治疗可挽救神经退行性变和视觉功能。
Mol Ther. 2022 Apr 6;30(4):1421-1431. doi: 10.1016/j.ymthe.2022.01.035. Epub 2022 Jan 31.
10
DRP1 inhibition rescues retinal ganglion cells and their axons by preserving mitochondrial integrity in a mouse model of glaucoma.在青光眼小鼠模型中,动力相关蛋白1(DRP1)抑制通过维持线粒体完整性挽救视网膜神经节细胞及其轴突。
Cell Death Dis. 2015 Aug 6;6(8):e1839. doi: 10.1038/cddis.2015.180.

引用本文的文献

1
Next-Gen Neuroprotection in Glaucoma: Synergistic Molecules for Targeted Therapy.青光眼的新一代神经保护:用于靶向治疗的协同分子
J Clin Med. 2025 Aug 30;14(17):6145. doi: 10.3390/jcm14176145.
2
Genetically encoded biosensors of metabolic function for the study of neurodegeneration, a review and perspective.用于神经退行性疾病研究的代谢功能基因编码生物传感器:综述与展望
Neurophotonics. 2025 Jun;12(Suppl 2):S22805. doi: 10.1117/1.NPh.12.S2.S22805. Epub 2025 Sep 4.
3
Inorganic-bacterial biohybrids for efficient solar-driven nitrogen fixation.

本文引用的文献

1
Tolerance to NADH/NAD imbalance anticipates aging and anti-aging interventions.对NADH/NAD失衡的耐受性预示着衰老和抗衰老干预。
iScience. 2021 Jun 8;24(7):102697. doi: 10.1016/j.isci.2021.102697. eCollection 2021 Jul 23.
2
Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction.烟酰胺通过防止线粒体和代谢功能障碍为青光眼提供神经保护。
Redox Biol. 2021 Jul;43:101988. doi: 10.1016/j.redox.2021.101988. Epub 2021 Apr 24.
3
Lymphoblastoid Cell Lines as Models to Study Mitochondrial Function in Neurological Disorders.
用于高效太阳能驱动固氮的无机-细菌生物杂交体。
Nat Commun. 2025 Jul 1;16(1):5690. doi: 10.1038/s41467-025-60937-5.
4
NMN Supplementation Inhibits Endothelial Cell ROS-Mediated Src/Pi3k/Akt Signaling Pathway to Protect High-Altitude Blood-Retinal Barrier.补充烟酰胺单核苷酸可抑制内皮细胞活性氧介导的Src/磷脂酰肌醇-3激酶/蛋白激酶B信号通路,以保护高原血视网膜屏障。
Invest Ophthalmol Vis Sci. 2025 Apr 1;66(4):51. doi: 10.1167/iovs.66.4.51.
5
Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.用新兴疗法挑战青光眼:针对视力“隐形窃贼”的进展概述
Front Med (Lausanne). 2025 Mar 26;12:1527319. doi: 10.3389/fmed.2025.1527319. eCollection 2025.
6
The role of RGC degeneration in the pathogenesis of glaucoma.视网膜神经节细胞变性在青光眼发病机制中的作用。
Int J Biol Sci. 2025 Jan 1;21(1):211-232. doi: 10.7150/ijbs.103222. eCollection 2025.
7
Network-based hub biomarker discovery for glaucoma.基于网络枢纽生物标志物的青光眼发现。
BMJ Open Ophthalmol. 2024 Nov 12;9(1):e001915. doi: 10.1136/bmjophth-2024-001915.
8
Massively parallel sequencing of mitochondrial genome in primary open angle glaucoma identifies somatically acquired mitochondrial mutations in ocular tissue.原发性开角型青光眼中线粒体基因组的大规模平行测序确定了眼部组织中体细胞获得的线粒体突变。
Sci Rep. 2024 Nov 1;14(1):26324. doi: 10.1038/s41598-024-72684-6.
9
Local glycolysis supports injury-induced axonal regeneration.局部糖酵解支持损伤诱导的轴突再生。
J Cell Biol. 2024 Dec 2;223(12). doi: 10.1083/jcb.202402133. Epub 2024 Oct 1.
10
Nicotinamide: Bright Potential in Glaucoma Management.烟酰胺:青光眼治疗中的光明前景。
Biomedicines. 2024 Jul 25;12(8):1655. doi: 10.3390/biomedicines12081655.
淋巴母细胞系作为研究神经紊乱中线粒体功能的模型。
Int J Mol Sci. 2021 Apr 26;22(9):4536. doi: 10.3390/ijms22094536.
4
Tryptophan Pathway Abnormalities in a Murine Model of Hereditary Glaucoma.色氨酸代谢途径异常与遗传性青光眼的小鼠模型。
Int J Mol Sci. 2021 Jan 21;22(3):1039. doi: 10.3390/ijms22031039.
5
Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity.循环 NADH 还原应激标志物与线粒体疾病严重程度相关。
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI136055.
6
NAD metabolism: pathophysiologic mechanisms and therapeutic potential.NAD 代谢:病理生理机制与治疗潜力。
Signal Transduct Target Ther. 2020 Oct 7;5(1):227. doi: 10.1038/s41392-020-00311-7.
7
Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease.烟酰胺,一种聚[ADP-核糖]聚合酶1(PARP-1)抑制剂,作为治疗阿尔茨海默病的辅助疗法。
Front Aging Neurosci. 2020 Aug 13;12:255. doi: 10.3389/fnagi.2020.00255. eCollection 2020.
8
Gene Therapy Preserves Retinal Structure and Function in a Mouse Model of -Associated Retinal Degeneration.基因疗法在与[疾病名称]相关的视网膜变性小鼠模型中保留视网膜结构和功能。 (你提供的原文中“-Associated”处应该有具体疾病名称缺失,我按格式翻译了完整句子结构,你可补充完整准确内容)
Mol Ther Methods Clin Dev. 2020 Jul 9;18:582-594. doi: 10.1016/j.omtm.2020.07.003. eCollection 2020 Sep 11.
9
Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial.尼可酰胺(维生素 B3)补充治疗对青光眼患者内层视网膜功能的改善作用:一项交叉随机临床试验。
Clin Exp Ophthalmol. 2020 Sep;48(7):903-914. doi: 10.1111/ceo.13818. Epub 2020 Jul 28.
10
Retinal energy metabolism in health and glaucoma.健康与青光眼状态下的视网膜能量代谢
Prog Retin Eye Res. 2021 Mar;81:100881. doi: 10.1016/j.preteyeres.2020.100881. Epub 2020 Jul 23.